Empagliflozin10Mg Tab

DRUG4 trials

Sponsors

Duke University, Shahid Beheshti University of Medical Sciences, Aristotle University Of Thessaloniki, Rehab Werida

Conditions

Cardiovascular PreventionDiabetes Mellitus, Type 2EmpagliflozinHeart FailureHematocrit ChangeHemodialysisKidney Transplant; ComplicationsSGLT2-Inhibitors

Phase 2

CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients

TerminatedNCT04906213

Duke UniversityDiabetes Mellitus, Type 2, Kidney Transplant; Complications

Start: 2022-07-25End: 2026-01-22Updated: 2026-02-27

Unknown Phase

Empagliflozin in Heart Failure Dialysis Patients

CompletedNCT05967156

Shahid Beheshti University of Medical SciencesHeart Failure, Hemodialysis

Start: 2023-06-01End: 2025-06-03Updated: 2025-06-06

Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels

RecruitingNCT06284850

Aristotle University Of ThessalonikiCardiovascular Prevention, Empagliflozin, Hematocrit Change +2

Start: 2023-11-30End: 2025-11-30Target: 40Updated: 2024-02-29

ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling

CompletedNCT07379788

Rehab WeridaHeart Failure

Start: 2025-01-01End: 2026-03-01Updated: 2026-06-02